Compare Citius Pharmaceuticals Inc (CTXR) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Zeta Global Holdings Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Zeta Global Holdings Corp trades at $22.93 (market cap $5.62B). The key difference: Zeta Global Holdings Corp is far larger — about 383.9× Citius Pharmaceuticals Inc's market cap, and Zeta Global Holdings Corp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | ZETA | |
|---|---|---|
Market Cap | $14.64M | $5.62B |
Sector | Health | Technology |
52-Week High | $1.82 | $25.24 |
52-Week Low | $0.53 | $14.04 |
Enterprise Value | $10.86M | $5.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
ZETA trades at $21.87, up 1.77% today, with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats and accelerating revenue growth, reaching $1.3B in 2025. Recent AI partnerships with Palantir and OpenAI signal strategic transformation, though negative net margins and cash flow challenges persist. Technical indicators show bullish moving averages with RSI approaching overbought territory near 70.
ZETA presents growth potential through AI platform expansion but faces profitability challenges. The 27% upside to consensus price target of $27.50 offers opportunity, while negative margins and cash flow require monitoring. Investment thesis hinges on successful AI monetization versus ongoing margin pressure from agency-led channels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
